Gust Kilian M, Resch Irene, D'Andrea David
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel, Vienna.
Curr Opin Urol. 2018 Jan;28(1):25-28. doi: 10.1097/MOU.0000000000000465.
Immunotherapies for urological malignancies have made tremendous progress by targeting immune checkpoints and have been implemented in clinical practice nowadays. Though siginifcant number of patients does not respond to immunotherapy. Biomarkers could help to predict response to treatment, but are still under investigation. We reviewed the literature to identify relevant biomarkers in patient treated with immunotherapy.
A comprehensive search of PubMed through has been performed to identify important relevant publications from 2016 to 2017 on biomarkers for immunotherapies in urological cancers including reported clinical trials. In addition, abstracts of relevant oncological scientific meetings from 2017 have been implemented.
Checkpoint inhibitors have shown substantial improvement in the treatment of metastatic RCC and metastatic and locally advanced urothelial cancer. There is an unmet need for the development of predictive biomarkers in order to identify patients who are more likely to respond to therapy.
针对免疫检查点的泌尿生殖系统恶性肿瘤免疫疗法取得了巨大进展，目前已应用于临床实践。尽管有相当数量的患者对免疫疗法无反应。生物标志物有助于预测治疗反应，但仍在研究中。我们回顾了文献，以确定接受免疫疗法治疗的患者中的相关生物标志物。
通过全面检索PubMed，以确定2016年至2017年关于泌尿生殖系统癌症免疫疗法生物标志物的重要相关出版物，包括已报道的临床试验。此外，还纳入了2017年相关肿瘤学科学会议的摘要。
检查点抑制剂在转移性肾细胞癌以及转移性和局部晚期尿路上皮癌的治疗中已显示出显著改善。开发预测性生物标志物以识别更可能对治疗产生反应的患者的需求尚未得到满足。
